This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Treatments:Cancer
From Proteopedia
(Difference between revisions)
| Line 26: | Line 26: | ||
* Fareston - Generic: Toremifene | * Fareston - Generic: Toremifene | ||
* [[Nolvadex]] - Generic: [[Tamoxifen]] | * [[Nolvadex]] - Generic: [[Tamoxifen]] | ||
| + | =====mTOR inhibitor===== | ||
| + | * Rapamune - Generic: Sirolimus ([[Rapamycin]]) | ||
=====Multiple Receptor [[Tyrosine kinase]] ([[VEGFR]], PDGFR, [[EGFR]], KIT, Abl) Inhibitor===== | =====Multiple Receptor [[Tyrosine kinase]] ([[VEGFR]], PDGFR, [[EGFR]], KIT, Abl) Inhibitor===== | ||
* [[Gleevec]] - Generic: [[Imatinib]] | * [[Gleevec]] - Generic: [[Imatinib]] | ||
Revision as of 14:43, 17 July 2019
Anti-CD20 Monoclonal Antibody
Anti-melanoma Monoclonal Antibody
B-Raf Kinase Inhibitor
Chemotherapy
Dihydrofolate Reductase Inhibitor
Epidermal Growth Factor Receptor Inhibitor
Estrogen Receptor ModulatormTOR inhibitor
Multiple Receptor Tyrosine kinase (VEGFR, PDGFR, EGFR, KIT, Abl) Inhibitor
Vascular Endothelial Growth Factor Inhibitor
|
Proteopedia Page Contributors and Editors (what is this?)
David Canner, Alexander Berchansky, Michal Harel, Karsten Theis
